AV-GBM-1

Drug Profile

AV-GBM-1

Alternative Names: AV GBM 1

Latest Information Update: 12 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AiVita Biomedical
  • Class Antineoplastics; Cancer vaccines; Cell therapies; Dendritic cell vaccines; Immunotherapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration Malignant melanoma
  • Phase II Glioblastoma
  • Preclinical Cancer

Most Recent Events

  • 20 Jun 2018 Phase-II clinical trials in Glioblastoma (Newly diagnosed, Adjunctive treatment) in USA (Parenteral) (NCT03400917)
  • 14 Jun 2018 US.FDA approves IND application to conduct phase II study in Glioblastoma multiforme
  • 17 Jan 2018 Aivita Biomedical plans a phase II clinical trial for Glioblastoma (Newly diagnosed, Adjunctive treatment) in USA (NCT03400917)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top